Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older therapies, writes Julie Coleman for CNBC..Bristol Myers CEO Chris Boerner noted, “Unfortunately, until Cobenfy, we did not have a fundamentally new mechanism of action to treat those patients…We get efficacy on par with the best of the existing atypicals, but we don’t see the side effect profile that you see with those drugs,”added the CEO accoeding to the CNBC story..
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
Questions or Comments about the article? Write to editor@tipranks.com